Key Takeaways A Phase 3 trial of Gilead's injectable drug lenacapavir found it was 100% effective in preventing HIV infection in women. Gilead said the test results were so significant an independent monitor recommended the company give the drug to all participants. More testing is needed before Gilead can apply to the U.S. Food and Drug Administration for approval. Shares of Gilead surged Thursday following the news. Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm ann ...